A 65-year-old man with severe atopic dermatitis is evaluated for treatment with a JAK inhibitor. Which of the following is specifically included in the FDA boxed warning for JAK inhibitors approved for dermatological conditions?
- A Progressive multifocal leukoencephalopathy
- B Hepatitis B reactivation
- C Major adverse cardiovascular events ✓
- D Aplastic anemia
Correct answer: C. Major adverse cardiovascular events
Explanation
JAK inhibitors carry a boxed warning for malignancy, major adverse cardiovascular events, thrombosis, and mortality based on the ORAL Surveillance trial in rheumatoid arthritis, extrapolated to dermatological indications like atopic dermatitis. Progressive multifocal leukoencephalopathy is a known risk of biologics like natalizumab, Hepatitis B reactivation is associated with rituximab, and aplastic anemia is a rare effect of TNF inhibitors.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.